A Practical Guide to Drug Development in Academia (eBook)
XII, 176 Seiten
Springer International Publishing (Verlag)
978-3-319-02201-7 (ISBN)
'A lot of hard-won knowledge is laid out here in a brief but informative way. Every topic is well referenced, with citations from both the primary literature and relevant resources from the internet.' Review from Nature Chemical Biology
Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed 'too early' to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest. Each chapter broadly discusses an important topic in drug development, from preclinical work in assay design through clinical trial design, regulatory issues and marketing assessments. After the practical overview provided here, the reader is encouraged to consult more detailed texts on specific topics of interest.
'I would actually welcome it if this book's intended audience were broadened even more. Younger scientists starting out in the drug industry would benefit from reading it and getting some early exposure to parts of the process that they'll eventually have to understand. Journalists covering the industry (especially the small startup companies) will find this book a good reality check for many an over-hopeful press release. Even advanced investors who might want to know what really happens in the labs will find information here that might otherwise be difficult to track down in such a concentrated form.'
Daria Mochly-Rosen, Ph.D., is the George D. Smith Professor of Translational Medicine, the Senior Associate Dean for Research, and a Professor in the Department of Chemical and Systems Biology at Stanford University School of Medicine and the Co-director of SPARK. She received her Ph.D. from the Weizmann Institute of Science in Israel, and was a postdoctoral fellow in the department of biochemistry at UC Berkeley. She joined Stanford University in 1993 and served as the chair of her department for four years. In 2003, her lab's basic research led to the founding of KAI Pharmaceuticals, where she served as the CSO for one year, and as the chair of the Scientific Advisory Committee and a member of the Board of Directors after her return to academia. She also founded ALDEA Pharmaceuticals in 2011. In addition, Dr. Mochly-Rosen served on a variety of review groups including the Peer Review Advisory Committee of the NIH and on the Council of Councils of the NIH.
Kevin Grimes, M.D., M.B.A., received his M.D. from Brown University and his M.B.A. from Stanford University. After his training, he joined the Stanford faculty as an academic internist. He later worked in the medical device and biotechnology sectors before returning to academia. He is currently the Co-director of the SPARK Translational Research Program and Associate Professor of Chemical and Systems Biology at Stanford, where he also teaches drug discovery and development and the practice of internal medicine.
Daria Mochly-Rosen, Ph.D., is the George D. Smith Professor of Translational Medicine, the Senior Associate Dean for Research, and a Professor in the Department of Chemical and Systems Biology at Stanford University School of Medicine and the Co-director of SPARK. She received her Ph.D. from the Weizmann Institute of Science in Israel, and was a postdoctoral fellow in the department of biochemistry at UC Berkeley. She joined Stanford University in 1993 and served as the chair of her department for four years. In 2003, her lab’s basic research led to the founding of KAI Pharmaceuticals, where she served as the CSO for one year, and as the chair of the Scientific Advisory Committee and a member of the Board of Directors after her return to academia. She also founded ALDEA Pharmaceuticals in 2011. In addition, Dr. Mochly-Rosen served on a variety of review groups including the Peer Review Advisory Committee of the NIH and on the Council of Councils of the NIH. Kevin Grimes, M.D., M.B.A., received his M.D. from Brown University and his M.B.A. from Stanford University. After his training, he joined the Stanford faculty as an academic internist. He later worked in the medical device and biotechnology sectors before returning to academia. He is currently the Co-director of the SPARK Translational Research Program and Associate Professor of Chemical and Systems Biology at Stanford, where he also teaches drug discovery and development and the practice of internal medicine.
Chapter 1: Getting Started1.1 Advancing New Treatments to the Clinic within Academia Daria Mochly-Rosen1.2 Overview of Drug Discovery and Development Kevin Grimes1.3 Assessing Clinical Need Kevin Grimes1.4 Target Product Profile (TPP) Robert Lum1.5 Project Management and Project Planning Rebecca Begeley and Daria Mochly-Rosen Chapter 2: Discovery and Preclinical Work2.1 Robustness of Preclinical StudiesDaria Mochly-Rosen2.2 Repurposing Drugs Kevin Grimes2.3 Developing Assays for High Throughput Screening (HTS) Bruce Koch 2.4 Medicinal Chemistry and Lead Optimization Daniel A. Erlanson2.5 Vaccine Development Harry Greenberg2.6 When to Begin Animal Studies Daria Mochly-Rosen2.7 In vivo pharmacology: Multiple Roles in Drug Discovery Simeon Taylor2.8 Pharmacokinetics and ADME Properties Werner Rubas and Emily Egeler 2.9 Route of Administration and Drug FormulationTerrence F. Blaschke2.10 Preclinical Safety Studies Michael Taylor and Kevin Grimes Chapter 3: Preparing for the Clinic3.1 Regulatory Considerations in Product Development Carol Karp3.2 Manufacturing and Quality Control Susan Wade3.3 Technical Development and Manufacturing of Biological Products Mark Backer3.4 Clinical Trial Design Ted McCluskey3.5 Overview of Clinical Trials Ted McCluskey Chapter 4: Transferring Technology4.1 Intellectual Property Judy Mohr4.2 Working with the University Technology Transfer Office Katharine Ku4.3 Avoiding Conflicts of Interest Emily Egeler4.4 Working with the University Compliance Office Jennifer Swanton Brown, Nicholas Gaich, and Steven Alexander Chapter 5: Commercialization and Entrepreneurship5.1 Selecting the Market for Your Drug Lilliane Brunner Halbach5.2 Commercial Assessments Julie Papanek5.3 Making a Compelling Pitch to Potential Investors Leon Chen5.4 Venture Capital Funding Kevin Kinsella5.5 Not-For-Profit Drug Development Eugenio L. de Hostos5.6 Legal Aspects of a Start-up Biotechnology Company Alan C. Mendelson, Peter E. Boyd, and Christopher M. Reilly5.7 Founder Preferred Stock Scott M. Iyama and Stephen J. Venuto5.8 Plan, Organize, Motivate and Control John Walker Chapter 6: Concluding Thoughts6.1 A Call to Action: Changing How We Pursue Drug Discovery and Development Steven Schow
Erscheint lt. Verlag | 8.7.2014 |
---|---|
Reihe/Serie | SpringerBriefs in Pharmaceutical Science & Drug Development | SpringerBriefs in Pharmaceutical Science & Drug Development |
Zusatzinfo | XII, 176 p. 9 illus., 4 illus. in color. |
Verlagsort | Cham |
Sprache | englisch |
Themenwelt | Naturwissenschaften ► Chemie |
Technik | |
Schlagworte | academia • assay design • clinical trial • preclinical |
ISBN-10 | 3-319-02201-6 / 3319022016 |
ISBN-13 | 978-3-319-02201-7 / 9783319022017 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 1,7 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich